Known as the first anti-VEGF agent approved by the Food and Drug Administration (FDA) in 2004 for clinical use in colorectal cancer, bevacizumab has also been the first anti-VEGF agent to be evaluated in the treatment of ovarian cancer [4, 33]. The gene discussed is VEGFA; the disease is colorectal cancer.